The preventive effect of atorvastatin on paraquat-induced pulmonary fibrosis in the rats

Advanced Pharmaceutical Bulletin

Volumn 4, Issue 4, 2014, Pages 345-349

  Khodayar, Mohammad Javad ^a   Kiani, Milad ^a   Hemmati, Ali Asghar ^a   Rezaie, Anahita ^b   Zerafatfard, Mohammad Rahim ^a   Nooshabadi, Mohammad Reza Rashidi ^a   Goudarzi, Mehdi ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID CHAMRAN UNIVERSITY OF AHVAZ   (Iran)

Author keywords

Atorvastatin; Paraquat; Pulmonary fibrosis; Rat

Indexed keywords

ATORVASTATIN; HYDROXYPROLINE; MALONALDEHYDE; PARAQUAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; LIPID PEROXIDATION; LUNG FIBROSIS; LUNG WEIGHT; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TISSUE LEVEL;

EID: 84906258085     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2014.050     Document Type: Article

References (25)

1. Green FH. Overview of pulmonary fibrosis. Chest 2002;122(6 Suppl):334S-9S.
2. Kroegel C, Mock B, Hengst U, Reissig A. Interferon-gamma-1b: therapeutic option in advanced idiopathic pulmonary fibrosis? Respiration 2004;71(6):656-7.
3. Yao HW, Zhu JP, Zhao MH, Lu Y. Losartan attenuates bleomycin-induced pulmonary fibrosis in rats. Respiration 2006;73(2):236-42.
4. Rose MS, Smith LL, Wyatt I. Evidence for energy-dependent accumulation of paraquat into rat lung. Nature 1974;252(5481):314-5.
5. Forman HJ, Aldrich TK, Posner MA, Fisher AB. Differential paraquat uptake and redox kinetics of rat granular pneumocytes and alveolar macrophages. J Pharmacol Exp Ther 1982;221(2):428-33.
6. Smith LL. The toxicity of paraquat. Adverse Drug React Acute Poisoning Rev 1988;7(1):1-17.
7. Aldrich TK, Fisher AB, Cadenas E, Chance B. Evidence for lipid peroxidation by paraquat in the perfused rat lung. J Lab Clin Med 1983;101(1):66-73.
8. Carre P, Leophonte P. Cytokines and pulmonary fibroses. Rev Mal Respir 1993;10(3):193-207.
9. Melchiorri D, Reiter RJ, Sewerynek E, Hara M, Chen L, Nistico G. Paraquat toxicity and oxidative damage. Reduction by melatonin. Biochem Pharmacol 1996;51(8):1095-9.
10. Vijeyaratnam GS, Corrin B. Experimental paraquat poisoning: a histological and electron-optical study of the changes in the lung. J Pathol 1971;103(2):123-9.
11. Smith LL, Rose MS. A comparison of the effects of paraquat and diquat on the water content of rat lung and the incorporation of thymidine into lung DNA. Toxicology 1977;8(2):223-30.
12. Suntres ZE, Hepworth SR, Shek PN. Protective effect of liposome-associated alpha-tocopherol against paraquat-induced acute lung toxicity. Biochem Pharmacol 1992;44(9):1811-8.
13. Shahar E, Keidar I, Hertzeg E, Barzilay Z. Effectiveness of vitamin E and colchicine in amelioration of paraquat lung injuries using an experimental model. Isr J Med Sci 1989;25(2):92-4.
14. Kojima S, Miyazaki Y, Honda T, Kiyozumi M, Shimada H, Funakoshi T. Effect of L-cystine on toxicity of paraquat in mice. Toxicol Lett 1992;60(1):75-82.
15. Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag 2010;6:843-53.
16. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis C. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 2007;115(2):144-50.
17. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6(5):358-70.
18. Hemmati AA, Nazari Z, Samei M. A comparative study of grape seed extract and vitamin E effects on silica-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 2008;21(4):668-74.
19. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41(4):467-70.
20. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440-7.
21. Balakumar P, Mahadevan N. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br J Pharmacol 2012;165(2):373-9.
22. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res 2006;98(3):361-9.
23. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 2006;110(3):371-85.
24. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther 2009;8(7):6-15.
25. Zheng X, Cui XX, Avila GE, Huang MT, Liu Y, Patel J, et al. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice. Clin Cancer Res 2007;13(18 Pt 1):5480-7.